ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/gastric-and-oesophageal/advanced-metastatic/her2-negative/first-line
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Gastric and oesophageal - Advanced/metastatic / HER2-negative / First line
4
trial(s) found.
NCT07431281
Advanced
Phase 3
Recruiting
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in
First-Line
Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (
D9803C00001
)
anti-CLDN18.2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
fluoropyrimidine
Gastric cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07262619
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor
Naïve
Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors (
EIK1005-002
)
WRN inhibitor
anti-PD-1 monoclonal antibody
Cancer
Endometrial cancer
Gastric cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Solid tumour
dMMR solid cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - PASO Medical
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT07221149
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously
Untreated
Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (
CA266-0004
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Oesophageal adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06901531
Advanced
Phase 3
Recruiting
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in
First-line
Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive (
LUCERNA
)
anti-CLDN18.2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastroesophageal junction adenocarcinoma
VIC
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Recruitment Country and State
VIC (4)
NSW (3)
WA (2)
QLD (2)
ACT (1)
NZ (1)
SA (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (4)
Cancer Therapy Class
PD-1
100%
PD-1/PD-L1
100%
CLDN18.2
50%
TIGIT
25%
WRN
25%
PD-L1
25%
VEGFA
25%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3199 - Frankston - PASO Medical (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
Cancer Type
Cancer
Gastroesophageal cancer
Gastrointestinal cancer
Solid tumour
Upper gastrointestinal cancer
Gastric cancer
Oesophageal cancer
Thoracic cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Biomarker-defined solid tumour
Colorectal adenocarcinoma
Colorectal cancer
Endometrial cancer
Gynaecological cancer
Lower gastrointestinal cancer
MSI-H/dMMR solid tumour
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
dMMR solid cancer
Oesophageal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy